Hernlund Emma, Redig Josefine, Paulsson Björn, Rangert Derolf Åsa, Höglund Martin, Vertuani Simona, Juliusson Gunnar
ICON plc Stockholm Sweden.
Novartis Oncology Nordics Stockholm Sweden.
EJHaem. 2021 May 6;2(3):385-393. doi: 10.1002/jha2.208. eCollection 2021 Aug.
Acute myeloid leukemia (AML) is associated with a high economic and clinical burden. Recently novel therapies have been added to standard treatment regimens. Here, we evaluated the economic impact of AML up until the introduction of these novel therapies. Individual data on 2954 adult patients diagnosed from 2007 to 2015 from five Swedish national population-based registers were used, enabling analyses from diagnosis to either death or 5-year follow-up for survival, inpatient and outpatient costs, costs of prescribed drugs, sick leave, and early retirement. Costs per patient were stratified by age group, treatment options, and -ITD status. The expected 5-year costs per patient differed substantially between age groups. Patients aged 18-59 years had an expected mean cost per patient of €170,748, while age groups 60-69 years, 70-79 years, and >80 years incurred an expected mean cost of €92,252, €48,344, and €24,118, respectively, over 5 years. Patients <60 years undergoing stem cell transplantation had the highest costs (€228,525 over 5 years). About 60% of costs for these patients were from hospitalizations and 20% from sick leave and early retirement; cost per day was highest from the first admission to complete remission. This study provides a baseline for socioeconomic evaluations of novel therapies in AML in Sweden.
急性髓系白血病（AML）会带来高昂的经济和临床负担。最近，新型疗法已被纳入标准治疗方案。在此，我们评估了在这些新型疗法引入之前AML的经济影响。我们使用了来自瑞典五个全国性人口登记处的2954例2007年至2015年确诊的成年患者的个体数据，从而能够分析从诊断到死亡或5年随访期间的生存情况、住院和门诊费用、处方药费用、病假和提前退休情况。每位患者的费用按年龄组、治疗方案和 -ITD状态进行分层。不同年龄组患者的预期5年费用差异很大。18 - 59岁的患者预期人均费用为170,748欧元，而60 - 69岁、70 - 79岁和80岁以上的年龄组在5年内的预期人均费用分别为92,252欧元、48,344欧元和24,118欧元。接受干细胞移植的60岁以下患者费用最高（5年内为228,525欧元）。这些患者约60%的费用来自住院治疗，20%来自病假和提前退休；从首次入院到完全缓解期间每天的费用最高。本研究为瑞典AML新型疗法的社会经济评估提供了基线。
